Morita K, Takagi I
Dept. of Radiation Therapy, Aichi Cancer Center.
Gan No Rinsho. 1988 Oct;34(13):1887-91.
The clinical usefulness of bleomycin combined with irradiation was evaluated using 154 preoperatively treated cases with cancer of the esophagus. With the appearance rate Ef-3 (highly effective: no viable tumor cell in the esophageal specimen resected after preoperative treatment) the radiation effect was observed, in comparison with those three groups (30 Gy alone, 40 Gy alone and 30 Gy + 67.5 mg of bleomycin). Dose modifying actor (DMF) of bleomycin for the preoperatively irradiated esophageal cancer was 1.2-1.3. As a serious interstitial pneumonitis was sometimes caused by the administration of bleomycin, it was concluded that the usage of bleomycin combined with preoperative irradiation for cancer of the esophagus, is less useful than that for cancer of the uterine cervix and the head and neck region.
使用154例术前接受治疗的食管癌病例评估了博来霉素联合放疗的临床实用性。通过Ef-3出现率（高度有效：术前治疗后切除的食管标本中无存活肿瘤细胞）观察放疗效果，并与三组（单独30 Gy、单独40 Gy和30 Gy + 67.5 mg博来霉素）进行比较。博来霉素对术前放疗食管癌的剂量修正因子（DMF）为1.2 - 1.3。由于博来霉素给药有时会引起严重的间质性肺炎，得出结论：博来霉素联合术前放疗用于食管癌的效果不如用于宫颈癌和头颈部癌。
